Multicenter Evaluation of a New Peritoneal Dialysis Solution with a High Lactate and a Low Magnesium Concentration

1983 ◽  
Vol 3 (2) ◽  
pp. 63-65 ◽  
Author(s):  
Karl D. Nolph Barbara ◽  
Prowant Kenneth D ◽  
Serkes Linda Morgan ◽  
Betty Baker Chaim ◽  
Chary Tan Kathy Gham ◽  
...  
Keyword(s):  
Peritoneal Dialysis ◽  
Serum Magnesium ◽  
Magnesium Concentration ◽  
Low Magnesium ◽  
Dialysis Solution ◽  
Peritoneal Dialysis Solution ◽  
High Lactate

Four co-operating centers evaluated the effects of a new dialysis solution containing 40 mEq/1 of lactate and 0.5 mEq/1 of magnesium on serum total CO2 and magnesium concentrations. The new solution yielded significant increases in serum CO2 and decreases in serum magnesium compared to the standard (35 mEq/1 of lactate and 1.5 mEq/1 of magnesium) solution.

Hypomagnesemia in Continuous Ambulatory Peritoneal Dialysis Patients Dialyzed with a Low-Magnesium Peritoneal Dialysis Solution

1995 ◽  
Vol 15 (1) ◽  
pp. 61-64 ◽  
Author(s):  
A. Ahsan Ejaz ◽  
Andrew P. McShane ◽  
Vasant C. Gandhi ◽  
David J. Leehey ◽  
Todd S. Ing
Keyword(s):  
Peritoneal Dialysis ◽  
Continuous Ambulatory Peritoneal Dialysis ◽  
Serum Magnesium ◽  
Veterans Affairs ◽  
Normal Serum ◽  
Dialysis Patients ◽  
Factors Associated ◽  
Low Magnesium ◽  
Dialysis Solution ◽  
Peritoneal Dialysis Solution

Objective Previous studies have shown a decrease in serum magnesium (Mg) concentration when continuous ambulatory peritoneal dialysis (CAPD) patients previously maintained on a 1.0 –1.2 mEq/L Mg peritoneal dialysis solution (PDS) were dialyzed with a 0.5 mEq/L Mg PDS. However, the prevalence of hypomagnesemia in CAPD patients dialyzed with low-Mg PDS is unknown. Design A retrospective study to determine the prevalence of hypomagnesemia and the factors associated with its occurrence in CAPD patients dialyzed using a 0.5 mEq/L Mg PDS. Setting A CAPD unit in a large Veterans Affairs Hospital. Patients All our CAPD patients (33) enrolled over a 52month period. Results All patients had serum magnesium levels higher than 1.25 mEq/L prior to use of low-Mg PDS. Hypomagnesemia (serum Mg < 1.25 mEq/L) developed in 21/33 patients (64%) when a 0.5 mEq/L Mg PDS was employed. Hypomagnesemia developed a mean of 8.2 months after beginning treatments. The duration of dialysis and the number of episodes of peritonitis did not differ between patients with and those without hypomagnesemia. Serum albumin levels were significantly lower in patients with hypomagnesemia (2.5±0.12 g/dL vs 3.2±0.12, p < 0.01). Magnesium supplements were given to 13 patients; following this therapy, serum magnesium values became normal. Conclusions CAPD patients dialyzed with a 0.5 mEq/L Mg PDS may develop a considerable fall in serum magnesium level and may require magnesium supplements in order to restore normal serum values.

scholarly journals SGLT-2 inhibitors reduce glucose absorption from peritoneal dialysis solution by suppressing the activity of SGLT-2

2019 ◽  
Vol 109 ◽  
pp. 1327-1338 ◽  
Author(s):  
Ying Zhou ◽  
Jinjin Fan ◽  
Chenfei Zheng ◽  
Peiran Yin ◽  
Haishan Wu ◽  
...  
Keyword(s):  
Peritoneal Dialysis ◽  
Glucose Absorption ◽  
Dialysis Solution ◽  
Peritoneal Dialysis Solution

Stability of Ceftazidime and Vancomycin Alone and in Combination in Heparinized and Nonheparinized Peritoneal Dialysis Solution

1994 ◽  
Vol 28 (5) ◽  
pp. 572-576 ◽  
Author(s):  
Leigh M. Vaughan ◽  
Cathy Y. Poon
Keyword(s):  
Peritoneal Dialysis ◽  
Room Temperature ◽  
Color Change ◽  
Hplc Assay ◽  
Time Points ◽  
Stability Indicating ◽  
Dialysis Solution ◽  
Peritoneal Dialysis Solution ◽  
The Stability

OBJECTIVE: To examine the stability of ceftazidime, vancomycin, and heparin, alone and in combination, in dialysis solution over six days at three temperatures. DESIGN: Nine 250-mL Dianeal PD-2 dextrose 1.5% bags were prepared with ceftazidime, vancomycin, and heparin alone and in combination at set concentrations of 100 μg/mL, 50 μg/mL, and 1 unit/mL, respectively. Three bags of each mixture were stored at 4, 25, and 37°C. Duplicate samples for analysis were removed from each bag at the following time points: premix, 0, 12, 24, 48, 72, 96, 120, and 144 hours. MAIN OURCOME MEASURES: Each sample was examined visually for signs of cloudiness and precipitation. Each sample was analyzed by stability-indicating HPLC assay for ceftazidime and vancomycin, with stability defined as less than 10 percent degradation of drug overtime. RESULTS: No color change or precipitation was observed in any bag. Vancomycin with or without heparin was stable for 5–6 days at 4, 25, and 37°C. Ceftazidime with and without heparin was stable for 6 days at 4°C, 4 days at 25°C, and less than 12 hours at 37 °C. Vancomycin plus ceftazidime with and without heparin was stable for 6 days at 4 °C and 25°C, and 4–5 days at 37 °C, Ceftazidime plus vancomycin with or without heparin was stable for 6 days at 4°C, 2–3 days at 25°C, and 12 hours at 37 °C. CONCLUSIONS: Bulk preparations of ceftazidime and vancomycin, alone and in combination and with or without heparin in Dianeal PD dextrose 1.5% solution, are sufficiently stable for use up to 6 days under refrigeration or 48 hours at room temperature.

Insulin Efficacy with a New Bicarbonate/ Lactate Peritoneal Dialysis Solution

2000 ◽  
Vol 20 (4) ◽  
pp. 467-469 ◽  
Author(s):  
Paul Williams ◽  
Jo Mariott ◽  
Gerald Coles ◽  
Rachel Stead ◽  
Anders Tranæus ◽  
...  
Keyword(s):  
Peritoneal Dialysis ◽  
Dialysis Solution ◽  
Peritoneal Dialysis Solution

Effects of Peritoneal Dialysis Solution on Experimental Necrotizing Enterocolitis in Newborn Rats

2019 ◽  
Vol 1 (7) ◽  
pp. 547-551 ◽  
Author(s):  
Hatice Sonay Yalcin Comert ◽  
Haluk Sarihan ◽  
Ismail Saygin ◽  
Mustafa Imamoglu ◽  
Dilek Basar ◽  
...  
Keyword(s):  
Peritoneal Dialysis ◽  
Necrotizing Enterocolitis ◽  
Newborn Rats ◽  
Dialysis Solution ◽  
Peritoneal Dialysis Solution

Stability of ciprofloxacin in peritoneal dialysis solution

1992 ◽  
Vol 49 (12) ◽  
pp. 2956-2959
Author(s):  
W. Michael Mawhinney ◽  
Colin G. Adair ◽  
Sean P. Gorman ◽  
Barry McClurg
Keyword(s):  
Peritoneal Dialysis ◽  
Dialysis Solution ◽  
Peritoneal Dialysis Solution
Sign in / Sign up

Export Citation Format

Share Document